Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 6 of 6 entries
View as:

Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)

Phase: N/A Priority: Normal
NCT ID: NCT05092360 Org: User:
Start: 01/10/22 End: 05/31/27 Due: 05/31/28

A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)

Phase: N/A Priority: Normal
NCT ID: NCT03861793 Org: User:
Start: 02/26/19 End: 03/01/23 Due: 03/01/24

A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04144517 Org: User:
Start: 02/05/20 End: 01/07/22 Due: 01/07/23

Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)

Phase: N/A Priority: Normal
NCT ID: NCT04592653 Org: User:
Start: 09/30/20 End: 12/31/24 Due: 12/31/25

Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6

Phase: N/A Priority: Normal
NCT ID: NCT04830124 Org: User:
Start: 09/27/21 End: 05/08/25 Due: 05/08/26

A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02799095 Org: User:
Start: 09/14/16 End: 08/02/23 Due: 08/02/24